U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Esophageal Neuroendocrine Carcinoma

MedGen UID:
459488
•Concept ID:
C2987262
•
Neoplastic Process
Synonyms: Esophageal High Grade Neuroendocrine Carcinoma; Esophageal NEC; Esophageal NEC G3; Esophageal Poorly Differentiated Endocrine Carcinoma; Esophageal Small and Large Cell Endocrine Carcinoma

Definition

An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the esophagus. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVEsophageal Neuroendocrine Carcinoma

Professional guidelines

PubMed

Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y, Liao JT, Lin Y, Liu C, Wu ZH, Yu B, Sun S, Yu H, Hui XH, Wu XH, Zhao XM, Wang HJ, Zheng Q, Li Y, Hu ZH, Wang JL
J Dig Dis 2023 Aug-Sep;24(8-9):472-479. Epub 2023 Sep 16 doi: 10.1111/1751-2980.13219. PMID: 37596865
Progress in the treatment of esophageal neuroendocrine carcinoma.
Ma Z, Cai H, Cui Y
Tumour Biol 2017 Jun;39(6):1010428317711313. doi: 10.1177/1010428317711313. PMID: 28653897

Recent clinical studies

Etiology

The different prognostic factors between metastatic and nonmetastatic disease of esophageal neuroendocrine carcinoma.
Zhong L, Pan Y, Han S, Qi Q, Liao H, Jiang Y, Shen J
Indian J Cancer 2023 Oct 1;60(4):512-520. Epub 2024 Jan 10 doi: 10.4103/ijc.IJC_151_20. PMID: 38206083
Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y, Liao JT, Lin Y, Liu C, Wu ZH, Yu B, Sun S, Yu H, Hui XH, Wu XH, Zhao XM, Wang HJ, Zheng Q, Li Y, Hu ZH, Wang JL
J Dig Dis 2023 Aug-Sep;24(8-9):472-479. Epub 2023 Sep 16 doi: 10.1111/1751-2980.13219. PMID: 37596865
THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY.
Tustumi F, Marques SSB, Barros EF, Henriques AC, Waisberg J, Dias AR
Arq Gastroenterol 2022 Jan-Mar;59(1):53-57. doi: 10.1590/S0004-2803.202200001-10. PMID: 35442337
Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M, Saeki H, Kuwano H, Miyazaki T, Yokobori T, Sano A, Sakai M, Kakeji Y, Toh Y, Doki Y, Matsubara H
Ann Surg Oncol 2021 Nov;28(12):7983-7989. Epub 2021 Apr 11 doi: 10.1245/s10434-021-09872-5. PMID: 33843025
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H
Cancer Med 2020 Jan;9(2):595-604. Epub 2019 Dec 3 doi: 10.1002/cam4.2708. PMID: 31794158Free PMC Article

Diagnosis

Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y, Liao JT, Lin Y, Liu C, Wu ZH, Yu B, Sun S, Yu H, Hui XH, Wu XH, Zhao XM, Wang HJ, Zheng Q, Li Y, Hu ZH, Wang JL
J Dig Dis 2023 Aug-Sep;24(8-9):472-479. Epub 2023 Sep 16 doi: 10.1111/1751-2980.13219. PMID: 37596865
Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
Chen C, Hu H, Zheng Z, Yang Y, Chen W, Qiao X, Li P, Zhang S
Cancer Med 2022 Dec;11(24):4935-4945. Epub 2022 May 21 doi: 10.1002/cam4.4829. PMID: 35596661Free PMC Article
Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M, Saeki H, Kuwano H, Miyazaki T, Yokobori T, Sano A, Sakai M, Kakeji Y, Toh Y, Doki Y, Matsubara H
Ann Surg Oncol 2021 Nov;28(12):7983-7989. Epub 2021 Apr 11 doi: 10.1245/s10434-021-09872-5. PMID: 33843025
Esophageal neuroendocrine carcinoma complicated with unexpected hyperprocalcitonin: Case report and literature review.
Hu Q, Jin P, Zhao X, Wu W, Huang B, Shao S, Que R, Liang T
Medicine (Baltimore) 2018 Oct;97(40):e12219. doi: 10.1097/MD.0000000000012219. PMID: 30290592Free PMC Article
Progress in the treatment of esophageal neuroendocrine carcinoma.
Ma Z, Cai H, Cui Y
Tumour Biol 2017 Jun;39(6):1010428317711313. doi: 10.1177/1010428317711313. PMID: 28653897

Therapy

Anlotinib plus camrelizumab achieved long-term survival in a patient with metastatic esophageal neuroendocrine carcinoma.
Zhou L, Xu G, Chen T, Wang Q, Zhao J, Zhang T, Duan R, Xia Y
Cancer Rep (Hoboken) 2023 Sep;6(9):e1855. Epub 2023 Jun 28 doi: 10.1002/cnr2.1855. PMID: 37381647Free PMC Article
Esophageal Neuroendocrine Carcinoma With Pathological Complete Response After Neoadjuvant Chemotherapy Followed by Robot-assisted Surgery: A Case Report.
Hirano K, Hirohata R, Hamai Y, Yamaguchi S, Emi M, Yoshikawa T, Ohsawa M, Okada M
Anticancer Res 2023 Jul;43(7):3289-3293. doi: 10.21873/anticanres.16504. PMID: 37351985
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L, Liu Y, Gong L, Zhang M, Wu W
Cancer Biol Ther 2020 Nov 1;21(11):983-989. Epub 2020 Oct 23 doi: 10.1080/15384047.2020.1829265. PMID: 33092443Free PMC Article
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H
Cancer Med 2020 Jan;9(2):595-604. Epub 2019 Dec 3 doi: 10.1002/cam4.2708. PMID: 31794158Free PMC Article
Neuroendocrine carcinoma of the esophagus with an adenocarcinoma component.
Kaneko Y, Saito S, Takahashi K, Kanamaru R, Hosoya Y, Yamaguchi H, Kitayama J, Niki T, Lefor AK, Sata N
Clin J Gastroenterol 2019 Dec;12(6):534-538. Epub 2019 May 27 doi: 10.1007/s12328-019-00995-7. PMID: 31134449

Prognosis

The different prognostic factors between metastatic and nonmetastatic disease of esophageal neuroendocrine carcinoma.
Zhong L, Pan Y, Han S, Qi Q, Liao H, Jiang Y, Shen J
Indian J Cancer 2023 Oct 1;60(4):512-520. Epub 2024 Jan 10 doi: 10.4103/ijc.IJC_151_20. PMID: 38206083
Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y, Liao JT, Lin Y, Liu C, Wu ZH, Yu B, Sun S, Yu H, Hui XH, Wu XH, Zhao XM, Wang HJ, Zheng Q, Li Y, Hu ZH, Wang JL
J Dig Dis 2023 Aug-Sep;24(8-9):472-479. Epub 2023 Sep 16 doi: 10.1111/1751-2980.13219. PMID: 37596865
THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY.
Tustumi F, Marques SSB, Barros EF, Henriques AC, Waisberg J, Dias AR
Arq Gastroenterol 2022 Jan-Mar;59(1):53-57. doi: 10.1590/S0004-2803.202200001-10. PMID: 35442337
Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M, Saeki H, Kuwano H, Miyazaki T, Yokobori T, Sano A, Sakai M, Kakeji Y, Toh Y, Doki Y, Matsubara H
Ann Surg Oncol 2021 Nov;28(12):7983-7989. Epub 2021 Apr 11 doi: 10.1245/s10434-021-09872-5. PMID: 33843025
Progress in the treatment of esophageal neuroendocrine carcinoma.
Ma Z, Cai H, Cui Y
Tumour Biol 2017 Jun;39(6):1010428317711313. doi: 10.1177/1010428317711313. PMID: 28653897

Clinical prediction guides

Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.
Zhang Y, Liu X, Liang H, Liu W, Wang H, Li T
J Int Med Res 2023 Jul;51(7):3000605231187942. doi: 10.1177/03000605231187942. PMID: 37498227Free PMC Article
Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
Chen C, Hu H, Zheng Z, Yang Y, Chen W, Qiao X, Li P, Zhang S
Cancer Med 2022 Dec;11(24):4935-4945. Epub 2022 May 21 doi: 10.1002/cam4.4829. PMID: 35596661Free PMC Article
Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M, Saeki H, Kuwano H, Miyazaki T, Yokobori T, Sano A, Sakai M, Kakeji Y, Toh Y, Doki Y, Matsubara H
Ann Surg Oncol 2021 Nov;28(12):7983-7989. Epub 2021 Apr 11 doi: 10.1245/s10434-021-09872-5. PMID: 33843025
Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study.
Zhou Y, Hou P, Zha KJ, Wang F, Zhou K, He W, Gao JB
World J Gastroenterol 2020 Aug 21;26(31):4680-4693. doi: 10.3748/wjg.v26.i31.4680. PMID: 32884225Free PMC Article
A competing-risks nomogram and recursive partitioning analysis for cause-specific mortality in patients with esophageal neuroendocrine carcinoma.
Zhang G, Wu B, Wang X, Li J
Dis Esophagus 2019 Dec 30;32(11) doi: 10.1093/dote/doy129. PMID: 30715226

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...